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Purpose: The aim of the study was to develop a proniosomal carrier system for captopril for the 
treatment of hypertension that is capable of efficiently delivering entrapped drug over an extended 
period of time.  
Method: The potential of proniosomes as a transdermal drug delivery system for captopril was 
investigated by encapsulating the drug in various formulations of proniosomal gel composed of various 
ratios of sorbitan fatty acid esters, cholesterol, lecithin prepared by coacervation-phase separation 
method. The formulated systems were characterized in vitro for size, vesicle count, drug entrapment, 
drug release profiles and vesicular stability at different storage conditions. Stability studies for 
proniosomal gel were carried out for 4 weeks. 
Results: The method of proniosome loading resulted in an encapsulation yield of 66.7 - 78.7%. 
Proniosomes were characterised by transmission electron microscopy. In vitro studies showed 
prolonged release of entrapped captopril. At refrigerated conditions, higher drug retention was 
observed.  
Conclusion: It is evident from this study that proniosomes are a promising prolonged delivery system 
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INTRODUCTION 
To pursue optimal drug action, functional 
molecules could be transported by a carrier to 
the site of action and released to perform their 
task1. Non-ionic surfactant vesicles known as 
niosomes are microscopic lamellar structures 
formed on admixture of a non-ionic surfactant, 
cholesterol and dicetyl phosphate with 
subsequent hydration in aqueous media2. 
Proniosomes offer a versatile vesicle drug 
delivery concept with potential for delivery of 
drugs via transdermal route. This would be 
possible if proniosomes form niosomes upon 
hydration with water from skin following topical 
application under occlusive conditions3. 
Proniosomes minimizes problems of niosomes 
physical stability such as aggregation, fusion and 
leaking and provide additional convenience in 
transportation, storage and dosing4. 
Transdermal therapeutic system has generated 
an interest as this system provides the 
considerable advantage of a non-invasive 
parentral route for drug therapy, avoidance of 
first pass gut and hepatic metabolism, 
decreased side effects and relative ease of drug 
input termination in problematic cases 5. 
Captopril, an orally active inhibitor of an 
angiotensin-converting enzyme (ACE) has been 
widely used for the treatment of hypertension 
and congestive heart failure. The drug is 
considered a drug of choice in antihypertensive 
therapy due to its effectiveness and low toxicity 
6. Captopril shows 75% bioavailability but 
presence of food reduces the oral absorption by 
30-50%. According to a previous research, the 
oxidation rate of captopril in dermal homogenate 
is significantly lower than the intestinal 
homogenate because the oxidative product of 
captopril, a captopril disulfide shows poor 
absorption from the intestine 7. Captopril when 
administered initially causes hypotension, which 
can prove to be harmful in diuretic treated- and 
congestive heart failure patients. Persistent 
hypotension may cause some trouble in 
myocardial infraction patients 8. Therefore, the 
use of transdermal drug delivery system, can 
reduce the side effects associated with captopril. 
Niosome carriers, well known for their potential 
in topical drug delivery, have been used to 
transport captopril molecule in the skin layer. 
The objective of this study was to determine the 
factors influencing the encapsulation of captopril 
in proniosomal gel and to optimize encapsulation 





Captopril was a gift from Promed (Delhi, India). 
Soya lecithin, cholesterol, and dialysis tubing 
were purchased from Hi-Media Laboratories 
(Mumbai, India). Span 20, 40, 60, 80 and sorbitol 
were purchased from Central Drug House 
(Mumbai, India).    
Development of Proniosomal Gel 
Proniosomal gel was prepared by a 
coacervation-phase separation method 9. 
Precisely weighed amounts of surfactant, 
lecithin, cholesterol and drug were taken in a 
clean and dry wide mouthed glass vial of 5.0 ml 
capacity and alcohol (0.5 ml) was added to it. 
After warming, all the ingredients were mixed 
well with a glass rod; the open end of the glass 
bottle was covered with a lid to prevent the loss 
of solvent from it and warmed over water bath at 
60-70°C for about 5 min until the surfactant 
mixture was dissolved completely. Then the 
aqueous phase (0.1% glycerol solution) was 
added and warmed on a water bath till a clear 
solution was formed which was converted into 
proniosomal gel on cooling. The gel so obtained 
was preserved in the same glass bottle in dark 
conditions for characterization. Compositions of 
proniosomal gel formulations are given in Table 
1. 
 
Characterization of Proniosomal Gel 
Vesicle Size Analysis: Hydration of proniosomal 
gel (100mg) was done by adding saline solution 
(0.9% solution) in a small glass vial with 
occasional shaking for 10 min. The dispersion 
was observed under optical microscope 
(Olympus, New Delhi) at 100 x magnification. 
The sizes of 200-300 vesicles were measured 
using a calibrated ocular and stage micrometer 
(Erma, Tokyo) fitted in the optical microscope 9. 
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Rate of Spontaneity: Approximately 10 or 20 
mg of proniosomal gel was transferred to the 
bottom of a clean stoppered glass bottle and 
spread uniformly around the wall of the glass 
bottle with the help of a glass rod. At room 
temperature, 2 ml of phosphate saline (0.154 M 
NaCl) was added carefully along the walls of the 
glass bottle and  left in a test-tube stand 9. After 
20 minutes, a drop of this saline solution was 
withdrawn and placed on Neubauers Chamber 
(Marienfeld, Germany) to count the number of 
vesicles. The number of niosomes eluted from 
proniosomes were counted. 
Encapsulation Efficiency: To evaluate the 
loading capacity of proniosomal systems for 
captopril, proniosomal gel (100mg) was 
dispersed in distilled water and warmed a little 
for the formation of niosomes. Then the 
dispersion was centrifuged at 18000 rpm for 40 
min at 5oC (Remi CPR-24 centrifuge) 10. The 
clear fraction was used for the determination of 
free drug at 212 nm spectrophotometrically. The 
percentage encapsulation efficiency was 
calculated from Equation 1.  
% Encapsulation Efficiency=[1- (Unencapsulated 
drug / Total drug)] x 100 …(1) 
In Vitro Release: In vitro release studies on 
proniosomal gel were performed using locally 
manufactured Franz-diffusion cell. The capacity 
of receptor compartment was 15 ml. The area of 
donor compartment exposed to receptor 
compartment was 1.41cm2. The dialysis 
cellophane membrane (MMCO14KDC) was 
mounted between the donor and receptor 
compartment. A weighed amount of proniosomal 
gel was placed on one side of the dialysis 
membrane. The receptor medium was 
phosphate saline buffer pH 7.4. The receptor 
compartment was surrounded by a water jacket 
to maintain the temperature at 37±1oC. Heat was 
provided using a thermostatic hot plate with a 
magnetic stirrer. The receptor fluid was stirred by 
a Teflon-coated magnetic bead fitted to a 
magnetic stirrer (Bio-Craft Scientific Systems 
Pvt. Ltd., Agra) 9.  
At each sampling interval, samples were 
withdrawn and were replaced by equal volumes 
of fresh receptor fluid on each occasion. 
Samples withdrawn were analyzed 
spectrophotometrically (Shimadzu-1700) at 212 
nm. 
Stability Studies: The ability of vesicles to 
retain the drug (Drug Retention Behaviour) was 
assessed by keeping the proniosomal gel at 
three different temperature conditions, i.e., 
Refrigeration Temperature (4-80C), Room 
Temperature (25±20C) and oven (45±20C). 
Throughout the study, proniosomal formulations 
were stored in aluminium foil-sealed glass vials. 
The samples were withdrawn at different time 
intervals over a period of one month and drug 
leakage from the formulations was analyzed for 
drug content spectrophotometrically 11. 
 
RESULTS AND DISCUSSION 
Several novel carrier systems suggested as 
appropriate for captopril delivery include 
beadlets 12, microcapsules 13 bioadhesive 
system 14, floating tablets and capsules 15, 
semisolid matrix systems16, and microspheres17. 
Proniosomes have generated interest as a 
topical formulation as an approach to avoid the 
side effects associated with oral administration. 
To achieve the desirable therapeutic effect of 
proniosomes as drug carriers, they must be 
loaded with sufficient amount of active 
compound. Table 2 shows the effect of various 
sorbitan fatty acid esters and their ratio on the 
encapsulation of captopril in proniosomal gel. 
Captopril was best encapsulated by proniosomal 
prepared using Spans 40 and 60. This might be 
attributed to fact that Spans 40 and 60 are solid 
at room temperature and showed a higher phase 
transition temperatures [Tc] 18. The entrapment 
efficiency of Span 80 formulations was 11% less 
than those of Span 60. Spans 60 and 80 have 
the same head group, but Span 80 has an 
unsaturated alkyl chain.  Introduction of a double 
bond into the paraffin chain causes a marked 
enhancement in the permeability in liposomes. 
This might be the reason for the lower 
entrapment efficiency of the Span 80 system 19. 
Determination of vesicle size is important for the 
topical application of vesicles. Size was reduced 
when the dispersion was agitated. The reason 
for this is the energy applied in the agitation 
which results in the breakage of the larger 
vesicles to smaller vesicles. The size range was 
Gupta  et al  
 
Trop J Pharm Res, June 2007; 6 (2) 690
found to be 11.38 - 25.06 µm (without agitation) 
and 4.14 - 8.36 µm (with agitation). 
Vesicle size was found to be smallest in AGL11 
formulation (11.38±1.70 µm) due to the presence 
of Span 85.  Increasing hydrophobicity of the 
surfactant monomer led to a smaller vesicle, a 
result that is expected since surface energy 
decreases with increasing hydrophobicity 20. 
For spontaneity studies, the formulations in 
Table 2 were treated with ethanol, propanol, 
butanol and isopropanol. It was found that 
niosomes containing isopropanol and butanol 
Table 1: Composition of Proniosomal Gel Formulation 
 















1 AGL1 S20:S40 100:900 100 100 0.5 0.18 White Semi-solid 
2 AGL2 S20:S40 500:500 100 100 0.5 0.18 Light Brownish 
Semi-solid 
3 AGL3 S20:S40 900:100 100 100 0.5 0.18 Brown 
Transparent 
Liquid 
4 AGL4 S20:S60 100:900 100 100 0.5 0.18 White Semi-solid 
5 AGL5 S20:S60 500:500 100 100 0.5 0.18 White Semi-
Solid 
6 AGL6 S20:S60 900:100 100 100 0.5 0.18 Brown Liquid 
7 AGL7 S20:S65 100:900 100 100 0.5 0.18 Creamish 
Semisolid 
8 AGL8 S20:S65 500:500 100 100 0.5 0.18 Pale Yellow 
Semisolid 
9 AGL9 S20:S65 900:100 100 100 0.5 0.18 Brown Liquid 
10 AGL10 S40:S80 100:900 100 100 0.5 0.18 Creamish Liquid 
11 AGL11 S40:S80 500:500 100 100 0.5 0.18 Creamish Gel 
12 AGL12 S40:S80 900:100 100 100 0.5 0.18 Creamish 
Semisolid 
13 AGL13 S60:S80 100:900 100 100 0.5 0.18 Creamish Liquid 
14 AGL14 S60:S80 500:500 100 100 0.5 0.18 Creamish Gel 
15 AGL15 S60:S80 900:100 100 100 0.5 0.18 Yellowish Semi-
solid 
16 AGL16 S65:S80 100:900 100 100 0.5 0.18 Yellowish Gel 
17 AGL17 S65:S80 500:500 100 100 0.5 0.18 Yellowish Gel 
18 AGL18 S65:S80 900:100 100 100 0.5 0.18 Creamish 
Semisolid 
 
* Drug concentration used was 10 mg in each formulation 
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were formed more spontaneously than niosomes 
containing propanol and ethanol perhaps as a 
result of faster phase separation of isopropanol 
and butanol due to their lower solubility in water. 
This result is consistent with those from 
spontaneity studies of levonorgestrel in 
proniosomes 9. 
The morphology of niosomes derived from 
proniosomal gel was studied using Transmission 




Table 2: Encapsulation Efficiency of Various Proniosomal Gel Formulations loaded with Captopril 
 











(mm3 x 1000) 
1 AGL2 25.06±4.50 8.36±0.10 78.71(±1.48) 11.19±0.52 
2 AGL5 18.09±1.53 7.59±0.11 77.76(±1.51) 15.25±0.28 
3 AGL8 17.41±0.94 5.19±0.23 74.78(±1.72) 14.54±1.11 
4 AGL11 11.38±1.70 6.37±0.11 73.78(±2.51) 16.58±0.77 
5 AGL14 22.40±1.57 7.75±0.09 76.77(±1.54) 13.59±1.17 
6 AGL17 19.82±2.16 4.14±0.18 66.69(±1.57) 7.95±0.24 
 
       *Mean of three determinations 
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Figure 1: Comparative in-vitro release profile of        Figure 2: Stability study of AGL2 at different temperatures 




Figure 3: Electron Micrograph of AGL2 
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niosomes formed were spherical and 
homogenous. 
In vitro release studies are often performed to 
predict how a delivery system might work in an 
ideal situation as well as give some indications 
of its in vivo performance since drug release 
dictates the amount of drug available for 
absorption. The amount of drug released from 
different proniosomal gel formulation was found 
in the order of AGL2 > AGL5 > AGL14 > AGL8 > 
AGL11 > AGL17 as shown in Fig. 1.  It was 
found that AGL2 showed a controlled release 
property from 10 to 24 hours. The cumulative 
release was found to be 189.44 µg/cm2 and 
223.54 µg/cm2 at the 10th and 24th hour, 
respectively. The release rate was constant from 
the 10th to the 24th hour. Thus, the formulation 
exhibited zero order release over this period. 
This may be attributed to the fact that the 
molecules of Spans 40 and 60 are in an ordered 
gel state at the in vitro permeation condition of 
250C, while the formulation AGL2 showed 
significantly higher release since Span 85 is in 
the disordered liquid crystalline state under the 
same condition 21. The other formulations - 
AGL5, AGL8, AGL11, AGL14, AGL17 - also 
showed good controlled release properties. The 
amount of drug retained within the vesicles 
under defined conditions ultimately governs the 
shelf life of the drug. The results showed that 
proniosomal gel formulation was quite stable at 
refrigeration and room temperatures as not 
much leakage of drug was found at these 
temperatures (see Fig. 2). Percent drug retained 
at 450C might have decreased due to the melting 
of the surfactant (m.p.:  480C) and lipid present 
in the formulation. Therefore, the proniosomal 
gel formulations can be stored at either 
refrigeration or room temperature. 
CONCLUSION 
In conclusion, we can state that besides 
imparting controlled systemic transdermal 
delivery to captopril, proniosomal gel possesses 
high entrapment efficiency and utilizes alcohol, 
which itself can act as a penetration enhancer. 
The formulation procedure is simple and does 
not involve lengthy procedures and use of 
several pharmaceutically excipients. 
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